Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Many U.S. Adults Don't Get Enough Rest or Sleep
Only 29.6 percent of adults in four states (Delaware, Hawaii, New York and Rhode Island) reported no days of insufficient rest or sleep in the past 30 days, and 10.1 percent reported insufficient rest or sleep every day during the past month, according to a study that analyzed 2006 Behavioral Risk Factor data collected in those states.
The study also found that 24.8 percent of adults unable to work were more likely to have insufficient rest or sleep. The findings are outlined in this week's Morbidity and Mortality Weekly Report, published by the U.S. Centers for Disease Control and Prevention.
The article noted that 50 million to 79 million Americans suffer from chronic sleep disorders. Sleep disorders and sleep loss may be associated with mental distress, depression, anxiety, obesity, hypertension, diabetes, high cholesterol and certain risk behaviors such as smoking, heavy drinking and physical inactivity, the article added.
More studies and data are needed to assess the prevalence and national impact of insufficient rest or sleep on adults, the article said. Adults need seven to nine hours of sleep a night, according to the National Sleep Foundation.
FDA Approves Nexium for Young Children
The drug Nexium (esomeprazole magnesium) has been approved for short-term treatment of children ages one to 11 years with gastroesophageal reflux disease (GERD), the U.S. Food and Drug Administration said Thursday.
The approval includes delayed-release capsule and liquid forms of the drug.
Nexium belongs to a class of drugs called proton pump inhibitors (PPIs), which decrease stomach acid production and help heal erosions in the lining of the esophagus (erosive esophagitis).
The FDA said children prescribed this drug should be monitored by their doctors for side effects, which may include headache, diarrhea, abdominal pain, nausea, gas, constipation, dry mouth and sleepiness.
New Drug Approved to Treat Rare Inflammatory Disorders
The injected drug Arcalyst has been approved by the U.S. Food and Drug Administration for treatment of two rare cryopyrin-associated periodic syndromes, the Associated Press reported.
The inherited disorders, which affect about 300 people in the United States, can cause symptoms including joint pain, rashes and fever. One of them can also cause hearing loss and deafness.
Arcalyst, made by Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y., works by blocking a protein that can trigger inflammation. Respiratory infections and rashes at the injection site are the most common side effects associated with the drug.
The drug's approval came under the FDA's orphan-drug program, which gives companies seven years of exclusive marketing rights in return for developing treatments for rare diseases, the AP reported.
Cribs Recalled for Fall Risks
U.S. safety officials announced a recall of 24,000 Indonesian-made cribs on Thursday.